SEHK:6990Biotechs
A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After New Oncology Regulatory Milestones
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after fresh oncology pipeline news, including priority review for sacituzumab tirumotecan in lung cancer and clinical trial approval for bispecific antibody SKB118 in advanced solid tumors.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
These oncology updates come after a mixed stretch for the stock. A 1-day share price return of 1.27% lifted the HK$429.6 quote, but the 30-day share price return is down...